

Page 1

Kwon
10/65/216


=> dis his;d 16 que stat;d 17 que stat

(FILE 'HOME' ENTERED AT 11:06:30 ON 22 NOV 2005)

FILE 'REGISTRY' ENTERED AT 11:08:38 ON 22 NOV 2005

L1 STR
L2 19 S L1
L3 STR L1
L4 STR
L5 2 S L4
L6 320 S L3 FUL
L7 57 S L5 FUL

L3 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L6 320 SEA FILE=REGISTRY SSS FUL L3

100.0% PROCESSED 340 ITERATIONS
SEARCH TIME: 00.00.01

320 ANSWERS

L4 STR



NODE ATTRIBUTES:

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

Page 2

DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 17 18
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS UNLIMITED AT 17 18

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE
L7 57 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED 1082 ITERATIONS 57 ANSWERS
SEARCH TIME: 00.00.01

=> fil medl,biosis,embase,caplus;s atheroscleros? or monkeberg? medical calcific
sclerosis or arteriolosclerosis or atheroma or fatty streak(a)arterial orrestenosis
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	327.82	328.66

FILE 'MEDLINE' ENTERED AT 11:17:04 ON 22 NOV 2005

FILE 'BIOSIS' ENTERED AT 11:17:04 ON 22 NOV 2005
Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 11:17:04 ON 22 NOV 2005
Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'CAPLUS' ENTERED AT 11:17:04 ON 22 NOV 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

L8 46803 FILE MEDLINE
L9 57510 FILE BIOSIS
L10 69191 FILE EMBASE
L11 47306 FILE CAPLUS

TOTAL FOR ALL FILES

L12 220810 ATHEROSCLEROS? OR MONKEBERG? MEDICAL CALCIFIC SCLEROSIS OR ARTER
IOLOSCLEROSIS OR ATHEROMA OR FATTY STREAK(A) ARTERIAL ORRESTENOS
IS

=> del l8 y;del l9 y;del l10 y;del l11 y;del l12 y;s atheroscleros? or monkeberg?
medical calcific sclerosis or arteriolosclerosis or atheroma or fatty
streak(a)arterial or restenosis

L8 56335 FILE MEDLINE
 L9 68182 FILE BIOSIS
 L10 78978 FILE EMBASE
 L11 52051 FILE CAPLUS

TOTAL FOR ALL FILES

L12 255546 ATHEROSCLEROS? OR MONKEBERG? MEDICAL CALCIFIC SCLEROSIS OR ARTERIOLOSCLEROSIS OR ATHEROMA OR FATTY STREAK(A) ARTERIAL OR RESTENOSIS

=> s 16 and 112;s 17 and 112

L13 0 FILE MEDLINE
 L14 0 FILE BIOSIS
 L15 0 FILE EMBASE
 L16 8 FILE CAPLUS

TOTAL FOR ALL FILES

L17 8 L6 AND L12

L18 0 FILE MEDLINE
 L19 0 FILE BIOSIS
 L20 0 FILE EMBASE
 L21 2 FILE CAPLUS

TOTAL FOR ALL FILES

L22 2 L7 AND L12

=> dup rem 117

PROCESSING COMPLETED FOR L17

L23 8 DUP REM L17 (0 DUPLICATES REMOVED)

=> d 1-8 ibib abs hitstr;d 122 1-2 ibib abs hitstr

L23 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:1059360 CAPLUS

DOCUMENT NUMBER: 142:38231

TITLE: Preparation of thienopyridine-ethanolamine derivatives as antiviral agents

INVENTOR(S): Schnute, Mark E.; Cudahy, Michele M.; Eggen, Marijean; Anderson, David J.; Judge, Thomas M.; Kim, Euibong J.; Collier, Sarah A.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004106345	A2	20041209	WO 2003-US24802	20030827
WO 2004106345	A3	20050303		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


PRIORITY APPLN. INFO.: US 2002-408067P P 20020904

OTHER SOURCE(S): MARPAT 142:38231

GI



I



II

AB Title compds. I [wherein R1 = Cl, Br, F or cyano; R2 = (un)substituted alkyl or (CH2)mOCH2CH2OH; R3 = C1-2 alkyl; R4 = five-membered N/O/S(O)m-heteroaryl optionally fused to benzene or pyridine ring; R5 = H or C1-2 alkyl optionally substituted with OH; m = 1 or 2, and stereoisomers or pharmaceutically acceptable salts thereof] were prepared For example, II was synthesized as a racemate in several steps. Resolution and further purification gave (R)-II isomer. This isomer showed inhibitory activity against HCMV, HSV and VZV polymerases with IC50 (μM) values of 0.04, 0.09 and 0.03, resp. Therefore, I and pharmaceutical compns. thereof are useful as as herpesviral DNA polymerase inhibitors, and as antiviral agents, in particular, as agents against viruses of the herpes family.


IT 804510-51-8P 804511-05-5P, Rac-N-(4-Chlorobenzyl)-2-[[[2-hydroxy-2-(1H-pyrazol-3-yl)ethyl] (methyl)amino]methyl]-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of (hydroxyethyl)aminomethyl dihydrothienopyridines as antiviral agents)


RN 804510-51-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo-(9CI) (CA INDEX NAME)



RN 804511-05-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1H-pyrazol-3-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



IT 804510-54-1P 804510-57-4P 804510-60-9P

804510-63-2P 804510-66-5P 804510-69-8P

804510-72-3P 804510-75-6P 804510-81-4P

804510-84-7P 804510-87-0P 804510-90-5P

804510-93-8P 804510-96-1P 804510-99-4P

804511-02-2P 804511-08-8P, N-(4-Chlorobenzyl)-2-[[[(2R)-2-hydroxy-2-(1H-pyrazol-3-yl)ethyl] (methyl) amino]methyl]-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-11-3P,

N-(4-Chlorobenzyl)-7-ethyl-2-[[[(2R)-2-(2-furyl)-2-hydroxyethyl] (methyl) amino]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-14-6P, N-(4-Chlorobenzyl)-2-[[[(2R)-2-(2-furyl)-2-hydroxyethyl] (methyl) amino]methyl]-7-(2-methoxyethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-17-9P

804511-20-4P 804511-23-7P 804511-29-3P

804511-35-1P 804511-41-9P 804511-47-5P

804511-50-0P 804511-57-7P 804511-66-8P

804511-69-1P, N-(4-Chlorobenzyl)-2-[[[(2R)-2-(2-furyl)-2-hydroxyethyl] (methyl) amino]methyl]-4-oxo-7-propyl-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-78-2P, N-(4-Chlorobenzyl)-2-[[[2-(5-chloro-2-furyl)-2-hydroxyethyl] (methyl) amino]methyl]-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-84-0P,

N-(4-Chlorobenzyl)-2-[[[(2R)-2-(2-furyl)-2-hydroxyethyl] (methyl) amino]methyl]-7-(2-hydroxyethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-96-4P, N-(4-Chlorobenzyl)-2-[[[(2R)-2-(2-furyl)-2-hydroxyethyl] (methyl) amino]methyl]-7-[2-(2-hydroxyethoxy)ethyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-99-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of (hydroxyethyl)aminomethyl dihydrothienopyridines as antiviral agents)

RN 804510-54-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-


2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 804510-57-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(5-methyl-2-furanyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-60-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-(3-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-63-2 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-66-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-thienyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-69-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1H-pyrrol-2-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-72-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1-methyl-1H-pyrrol-2-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-75-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1-methyl-1H-imidazol-4-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-81-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1H-imidazol-4-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-84-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1H-indol-3-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-87-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-(2,5-dimethyl-3-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-90-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[(2-benzo[b]thien-3-yl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-93-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-(5-cyano-2-thienyl)-2-hydroxyethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-96-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-(5-cyano-2-thienyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-99-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-thiazolyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-02-2 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzothiazolyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-08-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(1H-pyrazol-3-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 804511-11-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 804511-14-6 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 804511-17-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 804511-20-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 804511-23-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-29-3 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-7-(2,3-dihydroxypropyl)-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-35-1 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-(2,3-dihydroxypropyl)-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 804511-41-9 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 804511-47-5 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 804511-50-0 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 804511-57-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-(4,5-dimethyl-2-furyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-66-8 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(5-phenyl-2-furyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-69-1 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo-7-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 804511-78-2 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(5-chloro-2-furanyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-84-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-(2-hydroxyethyl)-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 804511-96-4 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-[2-(2-hydroxyethoxy)ethyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 804511-99-7 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1H-imidazol-2-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



IT 292144-09-3, N-(4-Chlorobenzyl)-2-(hydroxymethyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 292144-10-6, N-(4-Chlorobenzyl)-7-methyl-2-[(morpholin-4-yl)methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of (hydroxyethyl)aminomethyl dihydrothienopyridines as antiviral agents)
 RN 292144-09-3 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 292144-10-6 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)



IT 672326-03-3P, N-(4-Chlorobenzyl)-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-2-(hydroxymethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 672326-05-5P, 2-(Chloromethyl)-N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 672326-07-7P, N-(4-Chlorobenzyl)-2-(hydroxymethyl)-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 672326-09-9P, N-(4-Chlorobenzyl)-2-(chloromethyl)-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 672326-11-3P, N-(4-Chlorobenzyl)-2-(hydroxymethyl)-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 672326-12-4P, N-(4-Chlorobenzyl)-2-


(chloromethyl)-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672326-13-5P**,
 N-(4-Chlorobenzyl)-2-(chloromethyl)-7-(2-hydroxyethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672326-15-7P**,
 N-(4-Chlorobenzyl)-7-ethyl-2-(hydroxymethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672326-17-9P**, N-(4-Chlorobenzyl)-2-(chloromethyl)-7-ethyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672326-18-0P**, N-(4-Chlorobenzyl)-7-propyl-2-(hydroxymethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672326-20-4P**, N-(4-Chlorobenzyl)-2-(chloromethyl)-7-propyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672326-22-6P**,
 N-(4-Chlorobenzyl)-2-(hydroxymethyl)-7-(2-methoxyethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672326-23-7P**,
 N-(4-Chlorobenzyl)-2-(chloromethyl)-7-(2-methoxyethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672949-78-9P**,
 N-(4-Chlorobenzyl)-2-(hydroxymethyl)-4-oxo-7-[2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]ethyl]-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **672949-80-3P**, N-(4-Chlorobenzyl)-2-(chloromethyl)-4-oxo-7-[2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]ethyl]-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide **804510-78-9P 804511-26-0P 804511-32-8P 804511-38-4P 804511-44-2P 804511-81-7P 804511-93-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (hydroxyethyl)aminomethyl dihydrothienopyridines as antiviral agents)


RN 672326-03-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-05-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-07-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 672326-09-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 672326-11-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 672326-12-4 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 672326-13-5 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 672326-15-7 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(hydroxymethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-17-9 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-18-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 672326-20-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 672326-22-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-23-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-78-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-[2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 672949-80-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 804510-78-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-[1-(triphenylmethyl)-1H-imidazol-4-yl]ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-26-0 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-32-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 804511-38-4 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 804511-44-2 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)



RN 804511-81-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 804511-93-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo-7-[2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 672326-01-1P, N-(4-Chlorobenzyl)-2-(chloromethyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (hydroxyethylamino)methyl dihydrothienopyridines as antiviral agents)



RN 672326-01-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



L23 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:220341 CAPLUS
 DOCUMENT NUMBER: 140:270842
 TITLE: Preparation of arylethanol(thienopyridinemethyl)amine derivatives as antiviral agents
 INVENTOR(S): Schnute, Mark E.; Cudahy, Michele M.; Ciske, Fred L.; Genin, Michael J.; Anderson, David J.; Judge, Thomas M.; Eggen, Marijean; Collier, Sarah A.
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022568	A1	20040318	WO 2003-US24807	20030827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004116464	A1	20040617	US 2003-649202	20030827
US 2005049245	A1	20050303	US 2003-649208	20030827
PRIORITY APPLN. INFO.:			US 2002-408206P	P 20020904
OTHER SOURCE(S):		MARPAT 140:270842		
GI				



AB Arylethanol(thienopyridinemethyl)amine derivs. of formula I [R1 = halo, CN; R2 = (substituted) alkyl, etc.; R3 = alkyl; R4 = H, (substituted) alkyl; Ar = (substituted) Ph, aryl] are prepared as antiviral agents, in particular, as agents against viruses of the herpes family. Thus, II was prepared, and had IC50 of 0.05 μ M against HCMV polymerase.

IT 672325-77-8P 672325-86-9P 672325-93-8P
672325-95-0P 672325-97-2P 672325-98-3P
672325-99-4P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylethanol(thienopyridinemethyl)amine derivs. as antiviral agents)

RN 672325-77-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 672325-86-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-(3-methoxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 672325-93-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2S)-2-(4-cyanophenyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 672325-95-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2S)-2-(3-cyanophenyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 672325-97-2 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2S)-2-[4-(dimethylamino)phenyl]-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672325-98-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-[4-(hydroxymethyl)phenyl]ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672325-99-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-(4-nitrophenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 672325-79-0P 672325-81-4P 672325-82-5P
672325-84-7P 672325-88-1P 672325-90-5P
672325-91-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aryloethanol(thienopyridinemethyl)amine derivs. as antiviral agents)

RN 672325-79-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 672325-81-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-(2,3-dihydroxypropyl)-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672325-82-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-7-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672325-84-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)

phenylethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672325-88-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672325-90-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo-7-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672325-91-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 292144-13-9

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)

(preparation of aryethanol(thienopyridinemethyl)amine derivs. as antiviral agents)

RN 292144-13-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



IT 672326-38-4P 672326-39-5P 672326-40-8P


672326-41-9P 672326-42-0P 672326-43-1P

RL: PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)

(preparation of aryethanol(thienopyridinemethyl)amine derivs. as antiviral agents)


RN 672326-38-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(3-methoxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-39-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-(4-cyanophenyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-40-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-(3-cyanophenyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672326-41-9 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-[4-(dimethylamino)phenyl]-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672326-42-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-[4-(hydroxymethyl)phenyl]ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

— OH


RN 672326-43-1 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(4-nitrophenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



IT 292144-09-3 292144-10-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of aryethanol(thienopyridinemethyl)amine derivs. as antiviral agents)
 RN 292144-09-3 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 292144-10-6 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)




IT 672326-01-1P 672326-03-3P 672326-05-5P
 672326-07-7P 672326-09-9P 672326-11-3P
 672326-12-4P 672326-13-5P 672326-15-7P
 672326-17-9P 672326-18-0P 672326-20-4P
 672326-22-6P 672326-23-7P 672326-26-0P
 672326-28-2P 672326-29-3P 672326-30-6P
 672326-32-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of arylethanol(thienopyridinemethyl)amine derivs. as antiviral agents)


RN 672326-01-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-03-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-05-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-07-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 672326-09-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 672326-11-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-(9CI) (CA INDEX NAME)




RN 672326-12-4 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]-(9CI) (CA INDEX NAME)




RN 672326-13-5 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 672326-15-7 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(hydroxymethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-17-9 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-18-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 672326-20-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 672326-22-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 672326-23-7 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 672326-26-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672326-28-2 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672326-29-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-


dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo-7-[2-
[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672326-30-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-
dihydro-7-methyl-2-[(methylamino)methyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 672326-32-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-[4-
(dimethylamino)phenyl]-2-oxoethyl]methylamino]methyl]-4,7-dihydro-7-methyl-
4-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:220340 CAPLUS

DOCUMENT NUMBER: 140:270841

Prepared by: Mary Hale @2-2507 Rem Bldg 1D86

TITLE: Preparation of heteroarylethanolamines as antiviral agents

INVENTOR(S): Fleck, Thomas J.; Schnute, Mark E.; Cudahy, Michele M.; Anderson, David J.; Judge, Thomas M.; Herrington, Paul M.; Nair, Sajiv K.; Scott, Allen; Perrault, William R.; Tanis, Steven P.; Nieman, James A.; Collier, Sarah A.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA; Fleck, Bruce Francis

SOURCE: PCT Int. Appl., 90 pp.
CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022567	A1	20040318	WO 2003-US24806	20030827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004110787	A1	20040610	US 2003-649301	20030827
PRIORITY APPLN. INFO.:			US 2002-408065P	P 20020904
OTHER SOURCE(S):			MARPAT 140:270841	
GI				



AB Title compds. [I; R1 = Cl, Br, F, cyano; R2 = alkyl, hydroxyalkyl, alkoxyalkyl, (CH₂)_mOCH₂CH₂OH; m = 1, 2; R3 = alkyl; R4 = (R6-substituted) (benzo-fused) C-bonded 6-membered heteroaryl containing 1-3 N atoms; R5 = H, alkyl, hydroxyalkyl; R6 = halo, OCF₃, cyano, NO₂, CONR₇R₈, NR₇R₈, OR₁₀, CO₂R₁₀, (unsatd.) (R9-substituted) alkyl, etc.; R7, R8 = H, (substituted) Ph, alkyl, cycloalkyl, etc.; R9 = O, OR₁₀, SR₁₀, halo, NR₇R₈, CO₂R₁₀, etc.; R₁₀ = H, alkyl, cycloalkyl, (substituted) Ph], were prepared Thus, N-(4-chlorobenzyl)-2-(chloromethyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide (preparation given), diisopropylethylamine, and 2-(methylamino)-1-pyridin-3-ylethanol hydrobromide were heated in DMF at 90° for 2 h to give N-(4-chlorobenzyl)-2-[[[(2-hydroxy-2-pyridin-3-ylethyl) (methyl) amino]methyl]-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide. The latter inhibited HCMV, HSV, and VSV polymerase with IC₅₀ = 0.16, 0.58, and 0.22 μM, resp.

IT 672949-14-3P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); USES (Uses)
(preparation of heteroarylethanamines as antiviral agents)

RN 672949-14-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(3-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo-, (+) - (9CI) (CA INDEX NAME)

Rotation (+).




IT 672949-12-1P 672949-16-5P 672949-18-7P
672949-20-1P 672949-22-3P 672949-24-5P
672949-26-7P 672949-28-9P 672949-30-3P
672949-32-5P 672949-34-7P 672949-36-9P
672949-38-1P 672949-40-5P 672949-42-7P
672949-44-9P 672949-46-1P 672949-48-3P
672949-50-7P 672949-52-9P 672949-54-1P
672949-57-4P 672949-59-6P 672949-61-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroarylethanamines as antiviral agents)


RN 672949-12-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(3-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-16-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(4-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-18-7 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-20-1 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 672949-22-3 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(6-methyl-2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-24-5 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-quinolinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-26-7 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-pyrimidinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-28-9 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyrimidinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 672949-30-3 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-pyrazinylethyl)methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-32-5 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-pyrazinylethyl)methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672949-34-7 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(3-pyridazinyl)ethyl)methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-36-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-[[2-hydroxy-2-pyrazinylethyl)methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-38-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-[[2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-40-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo-7-propyl- (9CI) (CA INDEX NAME)



RN 672949-42-7 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2-hydroxy-2-pyrazinylethyl)methylamino]methyl]-4-oxo-7-propyl- (9CI) (CA INDEX NAME)



RN 672949-44-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-(2,3-dihydroxypropyl)-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672949-46-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(3-hydroxypropyl)-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672949-48-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-


dihydro-7-(3-hydroxypropyl)-2-[[[2-hydroxy-2-(2-pyrimidinyl)ethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-50-7 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672949-52-9 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyrazinylethyl)methylamino]methyl]-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-54-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-[2-(2-hydroxyethoxy)ethyl]-2-[[[(2R)-2-hydroxy-2-(2-pyrazinylethyl)methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672949-57-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-fluorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 672949-59-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-cyanophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 672949-61-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-bromophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 292144-09-3 292144-10-6 672950-41-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of heteroarylethanamines as antiviral agents)


RN 292144-09-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-10-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 672950-41-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(dimethylamino)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




IT 672326-01-1P 672326-03-3P 672326-05-5P
 672326-07-7P 672326-09-9P 672326-11-3P
 672326-12-4P 672326-13-5P 672326-15-7P
 672326-17-9P 672326-18-0P 672326-20-4P
 672326-22-6P 672326-23-7P 672326-30-6P
 672949-78-9P 672949-80-3P 672950-21-9P
 672950-23-1P 672950-25-3P 672950-27-5P
 672950-29-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of heteroarylethanolamines as antiviral agents)


RN 672326-01-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-03-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-05-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-07-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 672326-09-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 672326-11-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 672326-12-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)




RN 672326-13-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-15-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(hydroxymethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-17-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-18-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 672326-20-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 672326-22-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-23-7 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 672326-30-6 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-[(methoxymethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-78-9 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-4-oxo-7-[2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]ethyl]- (9CI) (CA INDEX NAME)




RN 672949-80-3 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, 2-(chloromethyl)-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-[(methoxymethyl)-4-oxo- (9CI) (CA INDEX NAME)

chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]ethyl]- (9CI) (CA INDEX NAME)



RN 672950-21-9 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-[[methyl (2-oxo-2-pyrazinyloethyl)amino]methyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 672950-23-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672950-25-3 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinyl)ethyl)methylamino)methyl]-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672950-27-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-pyrimidinyl)ethyl)methylamino)methyl]-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)



RN 672950-29-7 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-pyrazinylethyl]methylamino]methyl]-4-oxo-7-[2-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:203665 CAPLUS
 DOCUMENT NUMBER: 140:229446
 TITLE: Method using heterocyclic carboxamide compounds for preventing or treating atherosclerosis or restenosis
 INVENTOR(S): Wathen, Michael W.; Wathen, Lynne K.
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA


SOURCE: PCT Int. Appl., 110 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019939	A1	20040311	WO 2003-US26973	20030828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004102473	A1	20040527	US 2003-651216	20030828
PRIORITY APPLN. INFO.:			US 2002-407090P	P 20020830
OTHER SOURCE(S): MARPAT 140:229446				
AB	The invention provides a method of treating atherosclerosis or restenosis in a mammal which comprises administering an effective amount of a thieno[2,3-b]pyridine carboxamide derivative or a pyrrolo[3,2,1-ij]quinoline carboxamide derivative			
IT	292143-70-5 292143-71-6 292143-72-7 292143-74-9 292143-76-1 292143-78-3 292143-79-4 292143-83-0 292143-85-2 292143-86-3 292143-90-9 292143-92-1 292143-94-3 292143-96-5 292143-98-7 292144-00-4 292144-02-6 292144-04-8 292144-06-0 292144-09-3 292144-10-6 292144-12-8 292144-13-9 292144-14-0 292144-16-2 292144-17-3 292144-18-4 292144-19-5 292144-20-8 292144-22-0 292144-23-1 292144-24-2 292144-25-3 292144-26-4 292144-27-5 292144-28-6 292144-29-7 292144-30-0 292144-31-1 292144-32-2			
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (heterocyclic carboxamide compds. for preventing or treating atherosclerosis or restenosis)				
RN	292143-70-5 CAPLUS			
CN	Thieno[2,3-b]pyridine-5-carboxamide, 2-bromo-N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)			




RN 292143-71-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-72-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-iodo-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-74-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(3-hydroxy-1-propynyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-76-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(4-hydroxy-1-butynyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-78-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-79-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-2-(3-hydroxy-1-propynyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-83-0 CAPLUS

CN Thieno[2,3-b]pyridine-7(4H)-acetic acid, 5-[[[(4-chlorophenyl)methyl]amino]carbonyl]-2-(3-hydroxy-1-propynyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-85-2 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(4-hydroxybutyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-86-3 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-2-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-90-9 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-iodo-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 292143-92-1 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(3-hydroxy-1-propynyl)-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-94-3 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(3-hydroxypropyl)-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-96-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-methyl-7-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292143-98-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(3-hydroxy-1-propynyl)-7-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-00-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(3-hydroxypropyl)-7-(1-methylethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-02-6 CAPLUS

CN Butanedioic acid, mono[3-[5-[[[(4-chlorophenyl)methyl]amino]carbonyl]-7-ethyl-4,7-dihydro-4-oxothieno[2,3-b]pyridin-2-yl]-2-propynyl] ester (9CI)
(CA INDEX NAME)



RN 292144-04-8 CAPLUS


CN 4-Morpholineacetic acid, 3-[5-[[[(4-chlorophenyl)methyl]amino]carbonyl]-7-ethyl-4,7-dihydro-4-oxothieno[2,3-b]pyridin-2-yl]-2-propynyl ester (9CI)
(CA INDEX NAME)




RN 292144-06-0 CAPLUS

CN Benzoic acid, 3-(4-morpholinylmethyl)-, 3-[5-[[[(4-chlorophenyl)methyl]amino]carbonyl]-7-ethyl-4,7-dihydro-4-oxothieno[2,3-b]pyridin-2-yl]-2-propynyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 292144-09-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(hydroxymethyl)-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-10-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-12-8 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo-2-(4-thiomorpholinylmethyl)- (9CI) (CA INDEX NAME)




RN 292144-13-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-14-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-phenylethyl)methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-16-2 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-17-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 292144-18-4 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(1-methylethyl)-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-19-5 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-fluorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-20-8 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-bromophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-22-0 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylcarbonyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-23-1 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo-7-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 292144-24-2 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(3-fluorophenyl)methyl]-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 292144-25-3 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo-7-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 292144-26-4 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo-7-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)



RN 292144-27-5 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo-7-[2-(1-pyrrolidinyl)ethyl]- (9CI)
 (CA INDEX NAME)




RN 292144-28-6 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo-7-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 292144-29-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-(4-morpholinylmethyl)-4-oxo-7-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 292144-30-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[2-(diethylamino)ethyl]-4,7-dihydro-2-(3-hydroxy-1-propynyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 292144-31-1 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[2-(diethylamino)ethyl]-4,7-dihydro-2-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 292144-32-2 CAPLUS

CN L-Valine, 3-[5-[[[(4-chlorophenyl)methyl]amino]carbonyl]-7-ethyl-4,7-dihydro-4-oxothieno[2,3-b]pyridin-2-yl]-2-propynyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:203660 CAPLUS

DOCUMENT NUMBER: 140:229445

TITLE: Method using heterocyclic carboxamides for preventing or treating **atherosclerosis** or **restenosis**

INVENTOR(S): Wathen, Michael W.; Wathen, Lynne K.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 190 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019933	A1	20040311	WO 2003-US26963	20030828
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004176366	A1	20040909	US 2003-651290	20030828
PRIORITY APPLN. INFO.:			US 2002-407563P	P 20020830
			US 2003-469630P	P 20030509

OTHER SOURCE(S): MARPAT 140:229445


AB The invention provides a method of preventing or treating **atherosclerosis** or **restenosis** in mammals, which comprises administering an effective amount of a heterocyclic carboxamide.

IT 292144-10-6 292144-14-0 292144-20-8


RL: AGR (Agricultural use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocyclic carboxamides for preventing or treating **atherosclerosis** or **restenosis**)

RN 292144-10-6 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 292144-14-0 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[2-(2-hydroxy-2-phenylethyl)methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 292144-20-8 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-bromophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:202648 CAPLUS
 DOCUMENT NUMBER: 138:238160
 TITLE: Preparation of 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents
 INVENTOR(S): Thorarensen, Atli
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2003020730	A1	20030313	WO 2002-US27738	20020829
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2452438	AA	20030313	CA 2002-2452438	20020829
US 2003100536	A1	20030529	US 2002-230891	20020829
US 6924283	B2	20050802		
EP 1421088	A1	20040526	EP 2002-757510	20020829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011557	A	20040713	BR 2002-11557	20020829
JP 2005502686	T2	20050127	JP 2003-525000	20020829
PRIORITY APPLN. INFO.:			US 2001-316129P	P 20010830
			WO 2002-US27738	W 20020829

OTHER SOURCE(S): MARPAT 138:238160
GI



AB The title compds. [I; R1 = Cl, Br, CN, NO2, F; R2 = H, aryl, heteroaryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl, etc.], useful for treating a herpesvirus infection, **atherosclerosis** or **restenosis**, were prepared Thus, treating II with Lawesson's reagent in the presence of KHMDS in dichloroethane/toluene afforded I [R1 = Cl; R2 = Me; R3 = morpholinomethyl; R4 = H] which showed IC50 of 0.91 μ M, 0.36 μ M and 0.13 μ M against HCMV, HSV and VZV polymerases, resp.


IT 292144-10-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides

as antiviral agents)

RN 292144-10-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:202647 CAPLUS

DOCUMENT NUMBER: 138:238159

TITLE: Preparation of 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents

INVENTOR(S): Thorarensen, Atli

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020729	A1	20030313	WO 2002-US27527	20020829
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2452431	AA	20030313	CA 2002-2452431	20020829
US 2003109542	A1	20030612	US 2002-230890	20020829
US 6620810	B2	20030916		
EP 1421089	A1	20040526	EP 2002-763566	20020829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011214	A	20040713	BR 2002-11214	20020829
JP 2005502685	T2	20050127	JP 2003-524999	20020829
PRIORITY APPLN. INFO.:			US 2001-316108P	P 20010830
			WO 2002-US27527	W 20020829

OTHER SOURCE(S): MARPAT 138:238159

GI



AB The title compds. [I; R1 = Cl, Br, CN, NO2, F; R2 = H, aryl, heteroaryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl, etc.], useful for treating a herpesvirus infection, **atherosclerosis** or **restenosis**, were prepared Thus, treating II with Lawesson's reagent in the presence of KHMDS in dichloroethane/toluene afforded 37% I [R1 = Cl; R2 = Me; R3 = morpholinomethyl; R4 = H] which showed IC50 of 0.63 μ M, 0.16 μ M and 0.08 μ M against HCMV, HSV and VZV polymerases, resp.


IT **292144-10-6**

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents)

RN 292144-10-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:202646 CAPLUS



DOCUMENT NUMBER: 138:238158

TITLE: Preparation of 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents

INVENTOR(S): Thorarensen, Atli

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020728	A1	20030313	WO 2002-US25858	20020814
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003100536	A1	20030529	US 2002-230891	20020829
US 6924283	B2	20050802		
PRIORITY APPLN. INFO.:			US 2001-316129P	P 20010830
OTHER SOURCE(S):			MARPAT 138:238158	
GI				




AB The title compds. [I; R1 = Cl, Br, CN, NO2, F; R2 = H, aryl, heteroaryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl, etc.], useful for treating a herpesvirus infection, **atherosclerosis** or **restenosis**, were prepared Thus, treating II with Lawesson's reagent in the presence of KHMDS in dichloroethane/toluene afforded I [R1 = Cl; R2 = Me; R3 = morpholinomethyl; R4 = H] which showed IC50 of 0.91 μ M, 0.36 μ M and 0.13 μ M against HCMV, HSV and VZV polymerases, resp.

IT 292144-10-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides
as antiviral agents)

RN 292144-10-6 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-2-(4-morpholinylmethyl)-4-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:203665 CAPLUS

DOCUMENT NUMBER: 140:229446

TITLE: Method using heterocyclic carboxamide compounds for preventing or treating **atherosclerosis** or **restenosis**

INVENTOR(S): Wathen, Michael W.; Wathen, Lynne K.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019939	A1	20040311	WO 2003-US26973	20030828
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004102473	A1	20040527	US 2003-651216	20030828
PRIORITY APPLN. INFO.:			US 2002-407090P	P 20020830

OTHER SOURCE(S): MARPAT 140:229446

AB The invention provides a method of treating **atherosclerosis** or **restenosis** in a mammal which comprises administering an effective amount of a thieno[2,3-b]pyridine carboxamide derivative or a pyrrolo[3,2,1-ij]quinoline carboxamide derivative

IT 388121-63-9 388121-67-3 388121-74-2


388121-75-3 388121-76-4 388121-77-5
 388121-78-6 388121-79-7 388121-80-0
 388121-81-1 388121-82-2 388121-85-5
 388121-86-6 388121-87-7 388121-88-8
 388121-89-9 388121-93-5 388121-94-6
 388121-95-7 388121-96-8 388121-97-9
 388121-98-0 388121-99-1 388122-00-7
 388122-01-8 388122-02-9 388122-03-0
 388122-04-1 388122-05-2 388122-06-3
 388122-07-4 388122-08-5 388122-09-6
 388122-10-9 388122-11-0 388122-12-1
 388122-13-2 388122-14-3 388122-15-4
 388122-16-5 388122-17-6 388122-18-7
 388122-20-1 388122-21-2 388122-22-3
 388122-23-4 388122-24-5 388122-25-6
 388122-26-7 388122-27-8 388122-28-9
 388122-29-0 388122-30-3 388122-31-4
 388122-32-5 388122-33-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(heterocyclic carboxamide compds. for preventing or treating
atherosclerosis or restenosis)


RN 388121-63-9 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(hydroxymethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-67-3 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(hydroxymethyl)-6-oxo-8-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 388121-74-2 CAPLUS


CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(hydroxymethyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-75-3 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(2-hydroxyethyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 388121-76-4 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[2-(4-morpholinyl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-77-5 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[2-(diethylamino)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-78-6 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[2-(4-methyl-1-piperazinyl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI)
(CA INDEX NAME)




RN 388121-79-7 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[2-(2-ethyl-1-piperidiny)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-80-0 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[3-(4-methyl-1-piperazinyl)propyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI)
(CA INDEX NAME)




RN 388121-81-1 CAPLUS


CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-2-[2-(1-piperidiny)ethyl]- (9CI) (CA INDEX NAME)




RN 388121-82-2 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-2-[3-(4-morpholinyl)propyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-85-5 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(1,1-dioxido-4-thiomorpholinyl)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-86-6 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(1,1-dioxido-4-thiomorpholinyl)methyl]-1-iodo-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 388121-87-7 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(3-hydroxypropyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-88-8 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, 2-[[[(aminocarbonyl)amino]methyl]-N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-89-9 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(1R)-1-hydroxyethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388121-93-5 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(methoxymethyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-94-6 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(ethylthio)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-95-7 CAPLUS


CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-2-[(phenylthio)methyl]- (9CI) (CA INDEX NAME)




RN 388121-96-8 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(methylamino)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 388121-97-9 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(dimethylamino)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-98-0 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(2-hydroxyethyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388121-99-1 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(2-hydroxyethyl)-6-oxo-8-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)




RN 388122-00-7 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[2-hydroxy-1-(hydroxymethyl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-01-8 CAPLUS


CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[1,2-dihydroxy-1-(hydroxymethyl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-02-9 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-
 [(ethyldisulfanyl)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX
 NAME)




RN 388122-03-0 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-
 [(ethyldisulfanyl)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX
 NAME)




RN 388122-04-1 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, 2-[[bis(2-
 hydroxyethyl)amino]methyl]-N-[(4-chlorophenyl)methyl]-8-(4-
 morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-05-2 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[(2-hydroxyethoxy)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-06-3 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(1,2-dihydroxyethyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-07-4 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-2-(1,2,3-trihydroxypropyl)- (9CI) (CA INDEX NAME)




RN 388122-08-5 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[3-hydroxy-2-(hydroxymethyl)propyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI)
 (CA INDEX NAME)



RN 388122-09-6 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-(hydroxymethyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-10-9 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-(2-hydroxyethyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-11-0 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-(3-hydroxypropyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-12-1 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-[2-(4-morpholinyl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-13-2 CAPLUS


CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-1-[2-(4-thiomorpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 388122-14-3 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 388122-15-4 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-[2-(4-methyl-1-piperazinyl)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-16-5 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-1-[2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 388122-17-6 CAPLUS


CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, 1-[(acetylamino)methyl]-N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)



RN 388122-18-7 CAPLUS


CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-[(1S)-1-hydroxyethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 388122-20-1 CAPLUS


CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-1-[(1H-imidazol-1-yl)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-21-2 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, 1-(1H-benzotriazol-1-ylmethyl)-N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI)
 (CA INDEX NAME)




RN 388122-22-3 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-1-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 388122-23-4 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-1-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 388122-24-5 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-2-[2-(3-oxo-1-azetidiny)ethyl]- (9CI) (CA INDEX NAME)



RN 388122-25-6 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[2-(3-hydroxy-1-azetidiny)ethyl]-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-26-7 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-(2,3-dihydroxypropyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)




RN 388122-27-8 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-
 [(1S)-1-hydroxyethyl]-8-(4-morpholinymethyl)-6-oxo- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.




RN 388122-28-9 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-
 [2-(1H-imidazol-1-yl)ethyl]-8-(4-morpholinymethyl)-6-oxo- (9CI) (CA
 INDEX NAME)



RN 388122-29-0 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-
 [2-(1H-imidazol-2-yl)ethyl]-8-(4-morpholinymethyl)-6-oxo- (9CI) (CA
 INDEX NAME)




RN 388122-30-3 CAPLUS
 CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-
 (4-morpholinymethyl)-6-oxo-2-[2-(1H-1,2,4-triazol-3-yl)ethyl]- (9CI) (CA
 INDEX NAME)




RN 388122-31-4 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-2-[2-(1H-tetrazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 388122-32-5 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-8-(4-morpholinylmethyl)-6-oxo-2-[2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 388122-33-6 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[5-[[[(4-chlorophenyl)methyl]amino]carboxyl]-8-(4-morpholinylmethyl)-6-oxo-6H-pyrrolo[3,2,1-ij]quinolin-2-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:203660 CAPLUS

DOCUMENT NUMBER: 140:229445

TITLE: Method using heterocyclic carboxamides for preventing or treating **atherosclerosis** or **restenosis**

INVENTOR(S): Wathen, Michael W.; Wathen, Lynne K.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 190 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019933	A1	20040311	WO 2003-US26963	20030828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004176366	A1	20040909	US 2003-651290	20030828
PRIORITY APPLN. INFO.:			US 2002-407563P	P 20020830
			US 2003-469630P	P 20030509

OTHER SOURCE(S): MARPAT 140:229445

AB The invention provides a method of preventing or treating **atherosclerosis** or **restenosis** in mammals, which comprises administering an effective amount of a heterocyclic carboxamide.


IT 388121-74-2

RL: AGR (Agricultural use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (heterocyclic carboxamides for preventing or treating **atherosclerosis** or **restenosis**)

RN 388121-74-2 CAPLUS

CN 6H-Pyrrolo[3,2,1-ij]quinoline-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-

(hydroxymethyl)-8-(4-morpholinylmethyl)-6-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> dis his

(FILE 'HOME' ENTERED AT 11:06:30 ON 22 NOV 2005)

FILE 'REGISTRY' ENTERED AT 11:08:38 ON 22 NOV 2005

L1 STR
L2 19 S L1
L3 STR L1
L4 STR
L5 2 S L4
L6 320 S L3 FUL
L7 57 S L5 FUL

FILE 'MEDLINE, BIOSIS, EMBASE, CAPLUS' ENTERED AT 11:17:04 ON 22 NOV 2005

L8 56335 FILE MEDLINE
L9 68182 FILE BIOSIS
L10 78978 FILE EMBASE
L11 52051 FILE CAPLUS

TOTAL FOR ALL FILES

L12 255546 S ATHEROSCLEROS? OR MONKEBERG? MEDICAL CALCIFIC SCLEROSIS OR AR
L13 0 FILE MEDLINE
L14 0 FILE BIOSIS
L15 0 FILE EMBASE
L16 8 FILE CAPLUS


TOTAL FOR ALL FILES

L17 8 S L6 AND L12
L18 0 FILE MEDLINE
L19 0 FILE BIOSIS
L20 0 FILE EMBASE
L21 2 FILE CAPLUS

TOTAL FOR ALL FILES

L22 2 S L7 AND L12
L23 8 DUP REM L17 (0 DUPLICATES REMOVED)

=> d l6 que stat;d l7 que stat
L3 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
 L6 320 SEA FILE=REGISTRY SSS FUL L3

100.0% PROCESSED 340 ITERATIONS
 SEARCH TIME: 00.00.01

320 ANSWERS

L4 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 MLEVEL IS CLASS AT 17 18
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS UNLIMITED AT 17 18

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE
 L7 57 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED 1082 ITERATIONS
 SEARCH TIME: 00.00.01

57 ANSWERS

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

117.50

446.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-7.30

-7.30

STN INTERNATIONAL LOGOFF AT 11:19:51 ON 22 NOV 2005